Detalhe da pesquisa
1.
A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies.
BMC Cancer
; 15: 171, 2015 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-25881079
2.
Regional copy number-independent deregulation of transcription in cancer.
Nat Genet
; 38(12): 1386-96, 2006 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17099711
3.
Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer.
BMC Cancer
; 14: 660, 2014 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-25208577
4.
Nonclinical selection criteria for maximizing yield of nucleic acid amplification tests in tuberculosis diagnosis.
J Clin Microbiol
; 50(8): 2592-5, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22622440
5.
Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response.
Mol Cancer Ther
; 17(12): 2507-2518, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30232143
6.
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers.
Clin Cancer Res
; 24(9): 2050-2059, 2018 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29066505
7.
Visualizing chromosomes as transcriptome correlation maps: evidence of chromosomal domains containing co-expressed genes--a study of 130 invasive ductal breast carcinomas.
Cancer Res
; 65(4): 1376-83, 2005 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15735024
8.
Tumour invasion and metastasis: challenges facing drug discovery.
Curr Opin Pharmacol
; 5(4): 374-81, 2005 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-15955738
9.
Inhibition of human bladder tumour cell growth by fibroblast growth factor receptor 2b is independent of its kinase activity. Involvement of the carboxy-terminal region of the receptor.
Oncogene
; 23(57): 9201-11, 2004 Dec 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-15516981
10.
Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
Mol Cancer Ther
; 12(1): 16-26, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23144237
11.
Inhibition of Src impairs the growth of met-addicted gastric tumors.
Clin Cancer Res
; 16(15): 3933-43, 2010 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20628031
12.
Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer.
Clin Cancer Res
; 16(16): 4165-77, 2010 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20682712
13.
Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
Clin Cancer Res
; 16(19): 4876-83, 2010 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20805299
14.
Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia Function.
J Cancer Sci Ther
; 1(2): 52-61, 2009 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-20505783
15.
Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530.
Mol Oncol
; 3(3): 248-61, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19393585
16.
Estimated costs of false laboratory diagnoses of tuberculosis in three patients.
Emerg Infect Dis
; 8(11): 1264-70, 2002 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-12453354